The technology I'm referring to is the isolation and verification of DNA, RNA, micro-RNA, from all types of biological systems. Very early on, I out-licensed to Agilent Technologies one particular application utilizing our technology, and I used the revenue from that out-licensing to fuel the company's growth. I turned around and licensed an additional application into toxin removal for injectables to another company and used that revenue to fuel the company's growth.
Very often, when you have a patent application, you have broad claims, and you cannot exploit all these claims as a small company. In my case, I exploited what we were good at. What we're good at is mainly producing tools for scientists all over the world. My employees are just scientists, and these scientists simply know how to do science in the lab. They put it in a box and we sell it. We commercialize tools. Our biggest purchasers of these tools are from all over, but mainly the U.S.